Abstract
The pregnane X receptor (PXR) is a member of the nuclear receptor family of ligand-regulated transcription factors. Like many former orphan nuclear receptors, it contains both DNA and ligand binding domains and binds to response elements in the regulatory regions of target genes as a heterodimer with RXRα. Unlike the vast majority of nuclear receptors, however, PXR responds to a wide variety of chemically distinct xenobiotics and endobiotics, regulating the expression of genes central to both drug and bile acid metabolism. We review the structural basis of PXRs promiscuity in ligand binding, its recruitment of transcriptional coregulators, its potential formation of higher-order nuclear receptor complexes, and its control of target gene expression. Structural flexibility appears to be central to the receptors ability to conform to ligands that differ both in size and shape. We also discuss the clinical implications of PXRs role in the drugdrug interactions, cancer, and cholestatic liver disease.
Keywords: promiscuity, structural flexibility, drug metabolism, polymorphism, cancer, drug interactions, cholestasis, transcription
Current Drug Metabolism
Title: Structure and Function of the Human Nuclear Xenobiotic Receptor PXR
Volume: 6 Issue: 4
Author(s): V. E. Carnahan and M. R. Redinbo
Affiliation:
Keywords: promiscuity, structural flexibility, drug metabolism, polymorphism, cancer, drug interactions, cholestasis, transcription
Abstract: The pregnane X receptor (PXR) is a member of the nuclear receptor family of ligand-regulated transcription factors. Like many former orphan nuclear receptors, it contains both DNA and ligand binding domains and binds to response elements in the regulatory regions of target genes as a heterodimer with RXRα. Unlike the vast majority of nuclear receptors, however, PXR responds to a wide variety of chemically distinct xenobiotics and endobiotics, regulating the expression of genes central to both drug and bile acid metabolism. We review the structural basis of PXRs promiscuity in ligand binding, its recruitment of transcriptional coregulators, its potential formation of higher-order nuclear receptor complexes, and its control of target gene expression. Structural flexibility appears to be central to the receptors ability to conform to ligands that differ both in size and shape. We also discuss the clinical implications of PXRs role in the drugdrug interactions, cancer, and cholestatic liver disease.
Export Options
About this article
Cite this article as:
Carnahan E. V. and Redinbo R. M., Structure and Function of the Human Nuclear Xenobiotic Receptor PXR, Current Drug Metabolism 2005; 6 (4) . https://dx.doi.org/10.2174/1389200054633844
DOI https://dx.doi.org/10.2174/1389200054633844 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Assessing Drug Transport Across the Human Placental Barrier: From In Vivo and In Vitro Measurements to the Ex Vivo Perfusion Method and In silico Techniques
Current Pharmaceutical Biotechnology SALL4: Engine of Cell Stemness
Current Gene Therapy Berberine as a Promising Safe Anti-Cancer Agent- Is there a Role for Mitochondria?
Current Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Recent Developments on 1,2,4-Triazole Nucleus in Anticancer Compounds: A Review
Anti-Cancer Agents in Medicinal Chemistry Computational and Synthetic Biology Approaches for the Biosynthesis of Antiviral and Anticancer Terpenoids from <i>Bacillus subtilis</i>
Medicinal Chemistry Endoglin-Targeted Cancer Therapy
Current Drug Delivery miR-143: A Novel Regulator of MyoD Expression in Fast and Slow Muscles of Siniperca chuatsi
Current Molecular Medicine An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Thrombophilia and Female Sex Hormones
Current Women`s Health Reviews Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies
Anti-Cancer Agents in Medicinal Chemistry Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery MicroRNA: The Potential Regulator of Endometrial Carcinogenesis
MicroRNA Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry Stem Cell Therapies
Recent Patents on Regenerative Medicine Bioavailability Challenges Associated with Development of Anti-Cancer Phenolics
Mini-Reviews in Medicinal Chemistry Recent Evidence on the Role of Dietary PUFAs in Cancer Development and Prevention
Current Medicinal Chemistry A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets